Stockreport

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tol [Read more]